Fig. 2From: MS275 as Class I HDAC inhibitor displayed therapeutic potential on malignant ascites by iTRAQ-based quantitative proteomic analysisCell cycle analysis of MS275 treated cancer cells. Percentage of S180 (A, C) and H22 (B, C) cells in each mitotic phase after treatment with 0 μM, 2.5 μM, 5 μM MS275 for 24 h. Three independent measurements are repeated, and mean value is presented in (C)Back to article page